DMAC
DiaMedica Therapeutics Achieves Significant Progress Across Pipeline, Highlights Positive Interim Results for Preeclampsia Program
DiaMedica Therapeutics recently concluded a productive year across its pipeline, achieving key milestones and delivering promising results. The company's President and Chief Executive Officer, Rick Pauls, highlighted the progress made in 2025 during the fiscal year's earnings conference call. In his opening remarks, Mr. Pauls emphasized